KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Treasury Shares (2016 - 2025)

Sarepta Therapeutics has reported Treasury Shares over the past 1 years, most recently at $25.3 million for Q4 2025.

  • For Q4 2025, Treasury Shares changed N/A year-over-year to $5.6 million; the TTM value through Dec 2025 reached $5.6 million, changed N/A, while the annual FY2025 figure was $5.6 million, N/A changed from the prior year.
  • Treasury Shares for Q4 2025 was $5.6 million at Sarepta Therapeutics, up from $650876.0 in the prior quarter.
  • Over five years, Treasury Shares peaked at $5.6 million in Q4 2025 and troughed at -$651000.0 in Q2 2025.
  • A 4-year average of $1.8 million and a median of $1.6 million in 2021 define the central range for Treasury Shares.
  • Biggest five-year swings in Treasury Shares: surged 39.4% in 2021 and later grew 22.46% in 2023.
  • Year by year, Treasury Shares stood at $1.3 million in 2021, then soared by 38.59% to $1.8 million in 2022, then rose by 22.46% to $2.2 million in 2023, then skyrocketed by 149.84% to $5.6 million in 2025.
  • Business Quant data shows Treasury Shares for SRPT at $25.3 million in Q4 2025, $25.3 million in Q3 2025, and $25.3 million in Q2 2025.